Astrazeneca (AZN) Cash & Current Investments (2009 - 2026)

Astrazeneca (AZN) has reported Cash & Current Investments for 18 consecutive years, with $7.9 billion the latest figure, recorded in Q1 2026.

• In Q1 2026, Cash & Current Investments rose 45.99% year-over-year to $7.9 billion; the TTM figure through Mar 2026 stood at $7.9 billion (up 45.99% YoY), while the FY2025 annual figure was $6.2 billion, up 395.93% from the prior year.
• Cash & Current Investments came in at $7.9 billion for Q1 2026 at Astrazeneca, up from $6.2 billion in the prior quarter.
• The five-year high for Cash & Current Investments was $8.6 billion in Q3 2025, with the low at $1.3 billion in Q4 2024.
• Average Cash & Current Investments over 5 years is $6.0 billion, with a median of $6.0 billion recorded in 2023.
• Across the five-year window, Cash & Current Investments tumbled 78.98% in 2024 and soared 395.93% in 2025, its largest moves.
• Year by year, Cash & Current Investments stood at $6.3 billion in 2022, then declined by 4.75% to $6.0 billion in 2023, then sank by 78.98% to $1.3 billion in 2024, then jumped by 395.93% to $6.2 billion in 2025, then gained by 27.91% to $7.9 billion in 2026.
• According to Business Quant data, Cash & Current Investments over the past three periods registered $7.9 billion, $6.2 billion, and $8.6 billion for Q1 2026, Q4 2025, and Q3 2025 respectively.